Business
Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the National Institute of Allergy and Infectious Diseases (NIAID) SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the first subjects have been dosed in a Phase 1 clinical trial evaluating its StealthX™ exosome-based vac
About this update from Capricor Therapeutics, Inc.
[{"type":"image","alt":"Capricor Therapeutics","displaySize":"","headline":null,"caption":"Capricor Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YaI1GjtfVRH2kLVsjMQa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7","width":300,"height":107}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGen","length":90,"tagName":"p"}]},{"val":[{"type":"text","content":"Trial conducted and funded by the National Institute of Allergy and Infectious Diseases (NIAID)","length":95,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":185,"olType":false},{"type":"text","content":"SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the first subjects have been dosed in a Phase 1 clinical trial evaluating its StealthX™ exosome-based vaccine. The study, funded by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) under the U.S. Department of Health and Human Services’ Project NextGen, follows review and clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). The trial is being conducted by an NIAID-funded network of clinical trial sites.","length":719,"tagName":"p"},{"type":"text","content":"“The initiation of this study marks an important milestone in vaccine development as StealthX™ potentially offers an alternative to mRNA vaccines as this platform contains no adjuvants, offers a more natural delivery system, and uses native proteins, allowing for rapid adaptability to emerging targets,” said Linda Marbán, Ph.D., Chief Executive Officer of Capricor. “We are proud to collaborate with the NIH on this important trial, enabling us to evaluate the clinical profile of StealthX™ in humans for the first time. While the study is initially focused on SARS-CoV-2, our broader vision is to position StealthX™ as a versatile exosome-based platform ...